Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zain Chagla

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Annals of Internal Medicine|March 1, 2021
In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd doseZain Chagla
Annals of Internal Medicine|August 2, 2021
In patients with COVID-19, viral shedding time is 17 d and varies in some subgroupsZain Chagla
Annals of Internal Medicine|February 1, 2021
The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd doseZain Chagla
Annals of Internal Medicine|January 1, 2024
In outpatients with COVID-19 during Omicron variant circulation, molnupiravir and nirmatrelvir-ritonavir improved outcomesZain Chagla
Annals of Internal Medicine|March 1, 2021
In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd doseZain Chagla
Annals of Internal Medicine|February 3, 2025
In rifampicin-resistant TB, bedaquiline-containing regimens reduced unfavorable status vs. a control regimen at 132 wkAlex Nachman, Zain Chagla,
Annals of Internal Medicine|May 3, 2021
In South Africa, a 2-dose Oxford/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant)Neal Irfan, Zain Chagla
Annals of Internal Medicine|May 2, 2022
In high-risk outpatients with COVID-19, remdesivir reduced COVID-19-related hospitalization or all-cause death at 28 dOmar Mourad, Zain Chagla
Annals of Internal Medicine|April 3, 2023
In critically ill patients with COVID-19, IL-6 receptor antagonists reduced mortality vs. control at 180 dCharlotte Fuller, Zain Chagla
Annals of Internal Medicine|November 1, 2021
In patients hospitalized for COVID-19, tocilizumab reduces mortality at 28 dCarson K L Lo, Zain Chagla
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Annals of Internal Medicine|March 1, 2021
In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd doseZain Chagla
Annals of Internal Medicine|August 2, 2021
In patients with COVID-19, viral shedding time is 17 d and varies in some subgroupsZain Chagla
Annals of Internal Medicine|February 1, 2021
The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd doseZain Chagla
Annals of Internal Medicine|January 1, 2024
In outpatients with COVID-19 during Omicron variant circulation, molnupiravir and nirmatrelvir-ritonavir improved outcomesZain Chagla
Annals of Internal Medicine|March 1, 2021
In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd doseZain Chagla
Annals of Internal Medicine|February 3, 2025
In rifampicin-resistant TB, bedaquiline-containing regimens reduced unfavorable status vs. a control regimen at 132 wkAlex Nachman, Zain Chagla,
Annals of Internal Medicine|May 3, 2021
In South Africa, a 2-dose Oxford/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant)Neal Irfan, Zain Chagla
Annals of Internal Medicine|May 2, 2022
In high-risk outpatients with COVID-19, remdesivir reduced COVID-19-related hospitalization or all-cause death at 28 dOmar Mourad, Zain Chagla
Annals of Internal Medicine|April 3, 2023
In critically ill patients with COVID-19, IL-6 receptor antagonists reduced mortality vs. control at 180 dCharlotte Fuller, Zain Chagla
Annals of Internal Medicine|November 1, 2021
In patients hospitalized for COVID-19, tocilizumab reduces mortality at 28 dCarson K L Lo, Zain Chagla
Pageof 4